Plus Therapeutics has begun GMP manufacturing activities and technology transfer with SpectronRx, designating the company’s Indiana facility as a second production site for its radiopharmaceutical REYOBIQ. The partnership adds on‑demand production of the rhenium‑186 isotope and the drug product, complementing the existing site at Radiomedix.
The move is intended to bolster supply‑chain reliability and accelerate readiness for pivotal clinical trials and a potential commercial launch. By securing a second GMP site, Plus Therapeutics can mitigate risks associated with single‑source production, ensure timely supply for late‑stage studies, and position itself to meet the projected demand for REYOBIQ in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer trials.
Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, said the partnership “bolsters our manufacturing readiness and required expansion of our production capacity as we enter late‑stage development of REYOBIQ.” Anwer Rizvi, President of SpectronRx, added that the collaboration “strengthens a multi‑partner supply chain designed to deliver consistent, high‑quality product to patients.”
The announcement follows recent positive developments for the company, including regaining compliance with Nasdaq’s minimum bid price requirement after a 1‑for‑25 reverse stock split and receiving FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas. These milestones underscore the company’s focus on advancing its radiotherapeutic pipeline and securing the infrastructure needed to support future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.